替吉奥联合香菇多糖治疗老年胃癌临床观察  

Clinical efficacy of S-1 combined with lentinan in elderly patients with advanced gastric cancer

作　　者：余微[1] 王炜[1] 王晓湘[1] 孙梅芹[1] 张汝[1] 

机构地区：[1]成都军区总医院老年病科,成都610083

出　　处：《西南国防医药》2014年第5期471-473,共3页Medical Journal of National Defending Forces in Southwest China

基　　金：全军保健专项科研课题(11BJ31)

摘　　要：目的观察替吉奥联合香菇多糖治疗老年胃癌的疗效。方法选择＆gt;70岁的老年进展期胃癌患者27例,给予S-1（替吉奥）40～60 mg/m2口服,服药7 d后休息7 d,28 d为一个周期;香菇多糖2 mg静滴,2次/w;共用6个周期。结果全组患者均可评价疗效,部分缓解（PR）3例（11.11%）,病变稳定（SD）17例（63.96%）,进展（PD）7例（25.93%）,临床受益率（DCR）为75%;无进展生存时间（PFS）5.8个月（95%可信区间3.7～7.9）,总生存时间（OS）为11.8个月（95%可信区间6.1～17.5）。主要不良反应有贫血11例、白细胞减低8例、食欲下降13例和乏力6例,未影响治疗。结论替吉奥联合香菇多糖治疗老年胃癌疗效确切,耐受性良好,值得推广和进一步研究。Objective To evaluate the efficacy and toxicity of oteracil potassium（ S-1） combined with lentinan in elderly patients with advanced gastric cancer. Methods Twenty-seven elderly patients（ over 70 years of age） with advanced gastric cancer received S-1（ 40-60 mg /m2,7 days of oral administration followed by 7 days of withdrawal,28 days for a cycle）,as well as lentinan（ 2mg iv drip,twice a week）; there were a total of 6 chemotherapy cycles. Results Of all patients,3（ 11. 11%） achieved a partial remission,17（ 63. 96%） had stable disease,and 7（ 25. 93%） had progressive disease; the clinical benefit rate was 75%. The progression-free survival was 5. 8 months[95% confidence interval（ CI） 3. 7-7. 9 months]. The overall survival was 11. 8 months（ 95%CI 6. 1-17. 5 months）. The main adverse reactions included anemia（ 11 cases）,leucopenia（ 8 cases）,poor appetite（ 13 cases）,and fatigue（ 6 cases）,but they did not affect treatment. Conclusions Chemotherapy with S-1 plus lentinan has good efficacy and is well tolerable in elderly patients with advanced gastric cancer,and it is worthy of clinical application and further research.

关 键 词：老年 胃癌 替吉奥 化疗 毒性 

分 类 号：R735.2[医药卫生—肿瘤]